ARTICLE | Clinical News
Byetta exenatide regulatory update
March 6, 2006 8:00 AM UTC
The partners submitted an sNDA to FDA for Byetta injection as an adjunctive therapy to thiazolidinediones in Type II diabetes patients who are not achieving acceptable blood sugar control. The synthet...